Table 1.
Patient demographics and baseline characteristics, as-treated population
| Parameter | AML (n = 27) | MM (n = 18) | DLBCL (n = 22) | Total (N = 67) |
|---|---|---|---|---|
| Age, years, median (min, max) | 68.0 (37, 79) | 62.5 (51, 75) | 69.0 (43, 88) | 68.0 (37, 88) |
| Sex | ||||
| Female | 8 (29.6) | 4 (22.2) | 5 (22.7) | 17 (25.4) |
| Male | 19 (70.4) | 14 (77.8) | 17 (77.3) | 50 (74.6) |
| ECOG PS | ||||
| 0 | 6 (22.2) | 6 (33.3) | 7 (31.8) | 19 (28.4) |
| 1 | 21 (77.8) | 11 (61.1) | 14 (63.6) | 46 (68.7) |
| 2 | 0 | 1 (5.6) | 1(4.5) | 2 (3.0) |
| Racea | ||||
| n | 25 | 15 | 19 | 59 |
| Asian | 1 (4.0) | 0 | 8 (42.1) | 9 (15.3) |
| African American | 1 (4.0) | 1 (6.7) | 0 | 2 (3.4) |
| White | 21 (84.0) | 13 (86.7) | 10 (52.6) | 44 (74.6) |
| Other | 2 (8.0) | 1 (6.7) | 1 (5.3) | 4 (6.8) |
| Ethnicity | ||||
| n | 24 | 14 | 19 | 57 |
| Not Hispanic or Latino | 24 (100) | 14 (100) | 19 (100) | 57 (100) |
| Line of therapy for recurrent disease | ||||
| First line | 8 (29.6) | 0 | 2 (9.1) | 10 (14.9) |
| Second line | 9 (33.3) | 2 (11.1) | 2 (9.1) | 13 (19.4) |
| Third line or greater | 10 (37.0) | 16 (88.9) | 18 (81. 8) | 44 (65.7) |
| Prior stem cell/bone marrow transplant type | ||||
| Autologous | 0/3 | 12/13 (92.3) | 3/3 (100) | 15/19 (78.9) |
| Allogeneic | 3/3 (100) | 2/13 (15.4) | 0/3 | 5/19 (26.3) |
Data are presented as n (%) unless otherwise specified
AML acute myeloid leukemia, DLBCL diffuse large B-cell lymphoma, ECOG PS Eastern Cooperative Oncology Group performance status, max maximum, min minimum, MM multiple myeloma
aEach race category counts subjects who selected only that category